Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 22, 2013
- Accepted in final form January 6, 2014
- First Published April 4, 2014.
Article Versions
- Previous version (April 4, 2014 - 13:01).
- You are viewing the most recent version of this article.
Author Disclosures
- M. Toledano, MD,
- J.W. Britton, MD,
- A. McKeon, MD,
- C. Shin, MD,
- V.A. Lennon, MD, PhD,
- A.M.L. Quek, MBBS,
- E. So, MD,
- G.A. Worrell, MD, PhD,
- G.D. Cascino, MD,
- C.J. Klein, MD,
- T.D. Lagerlund, MD,
- E.C. Wirrell, MD,
- K.C. Nickels, MD and
- S.J. Pittock, MD
- M. Toledano, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- J.W. Britton, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Mr. and Mrs. David Hawk charitable gift for epilepsy research
NONE
NONE
NONE
NONE
NONE
NONE
- A. McKeon, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Guthy Jackson Charitable Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- C. Shin, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- V.A. Lennon, MD, PhD,
NONE
NONE
NONE
NONE
Dr. Lennon and Mayo Clinic have a financial interest in the following intellectual property: “Marker for Neuromyelitis Optica.” A patent has been issued for this technology, and it has been licensed to commercial entities. They have received cumulative royalties of greater than the federal threshold for significant financial interest from the licensing of these technologies. The author receives no royalties from the sale of these tests by Mayo Medical Laboratories; however, Mayo Collaborative Services, Inc. does receive revenue for conducting these tests.
NONE
NONE
NONE
NONE
NONE
Dr. Lennon is Director of the Mayo Neuroimmunology Laboratory that performs service testing for aquaporin-4 autoantibodies on behalf of Mayo Collaborative Service Inc., an agency of Mayo Foundation. Neither Dr. Lennon nor her laboratory benefit financially from this testing.
NONE
NIH R01-NS065829,?CNS Demyelinating Autoimmunity Targeting Water Channel Complexes?. Principal Investigator: S.J. Pittock Co-Investigator: V.A. Lennon Years: 2010-2015
NONE
NONE
NONE
“Marker for Neuromyelitis Optica”. A patent has been issued to Mayo Foundation for this technology, and it has been licensed to RSR/Kronus. Dr. Lennon has received cumulative royalties of greater than the federal threshold for significant financial interest from the licensing of these technologies.
Dr. Lennon has a potential financial interest in the technologies listed below: “Marker for Neuromyelitis Optica”.
NONE
NONE
NONE
- A.M.L. Quek, MBBS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- E. So, MD,
NONE
NONE
NONE
Journal of Clinical Neurophysiology, editorial board member, 4 years; Epilepsia, editorial board member, 2 years; Epilepsy Research, editorial board member, 3 years.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- G.A. Worrell, MD, PhD,
NeuroVista Inc.
NONE
NONE
Associate Editor of Transaction in Biomedical Engineering
Filed patent: Microscale Electrophysiology for mapping epileptogenic brain and predicting seizures
NONE
NONE
NONE
NONE
NONE
NONE
1) NeuroVista Inc. 2) Meditronic Inc.
NIH R01 NS 63039-1, PI: Worrell 04/01/2009 ? 03/31/2014 European Union Agreement FP 00066387 Co-I: Worrell 11/01/2011-12/31/2015 NeuroPace, Inc 15682PI: Worrell 11/01/2007 -?10/31/2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- G.D. Cascino, MD,
NONE
NONE
NONE
NEUROLOGY -- Associate Editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH R01 NS53998-03 (PI) grant (EPGP: Epilepsy Phenome Genome project)
NONE
NONE
NONE
NONE
(1) Mayo Foundation- Mayo Clinic Ventures-High frequency nerve stimulation to treat lower back pain, Nevro, 2013
NONE
NONE
NONE
- C.J. Klein, MD,
NONE
NONE
NONE
Editorial Board Journal of Peripheral Nerve Society.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
K08NS065007 funded by NINDS principal instigator IDENTIFICATION OF GENETIC CAUSES OF HEREDITARY SENSORY AND AUTONOMIC NEUROPATHIES Project Start Date: 1-SEP-2009 Project End Date: 30-AUG-2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- T.D. Lagerlund, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- E.C. Wirrell, MD,
Clobazam for Dravet syndrome study - all monies to Mayo with no personal reimbursement
NONE
NONE
Epilepsia Editorial Board 2010-2012, Journal of Child Neurology Editorial Board 2007-present
NONE
NONE
NONE
NONE
NONE
Biocodex - research support for multicenter US Stiripentol study in Dravet syndrome
NONE
NONE
NONE
NONE
Mayo Foundation, CR 20 Award, 2009-2011
NONE
NONE
NONE
NONE
NONE
NONE
- K.C. Nickels, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- S.J. Pittock, MD
NONE
NONE
NONE
NONE
Dr. Pittock and Mayo Clinic have a financial interest in the technology entitled “Aquaporin-4 Autoantibody as a Cancer Marker.” This technology has been licensed to a commercial entity but no royalties have been received. In addition, Dr. Pittock is an inventor of technology entitled “Aquaporin-4 Binding Autoantibodies in Patients with Neuromyelitis Optic Impair Glutamate Transport by Down-Regulating EAAT2.” Mayo Clinic has filed a non-provisional patent application for this technology.
NONE
NONE
Dr. Pittock has provided consultation to Alexion Pharmaceuticals, Medimmune and Chugai Pharma USA but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic.
NONE
NONE
NONE
Dr. Pittock has received a research grant from Alexion pharmaceuticals for his investigator-initiated study entitled “An Open Label Study of Eculizumab in NMO”
RO1 NS065829-01 entitled ?CNS Demyelinating Autoimmunity Targeting Water Channel Complexes?
NONE
Guthy Jackson Charitable Foundation grant for NMO research
NONE
NONE
NONE
NONE
NONE
NONE
- From the Departments of Neurology (M.T., J.W.B., A.M., C.S., V.A.L., E.S., G.A.W., G.D.C., C.J.K., T.D.L., E.C.W., K.C.N., S.J.P.), Laboratory Medicine and Pathology (A.M., V.A.L., A.M.L.Q., C.J.K., S.J.P.), and Immunology (V.A.L.), Mayo Clinic, College of Medicine, Rochester, MN.
- Correspondence to Dr. Pittock: pittock.sean{at}mayo.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
- Immunotherapy for pharmacoresistant epilepsy
- Nitin K. Sethi, Assistant Professor of Neurology, New York-Presbyterian Hospital, Weill Cornell Medical Center 525 East 68th Street, New York, NY 1006sethinitinmd@hotmail.com
- Nitin K Sethi, New York, NY
Submitted June 12, 2014 - Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy
- Michel Toledano, Mayo Clinictoledano.michel@mayo.edu
- Michel Toledano, Rochester, MN; Jeffrey W. Britton, Rochester, MN; Sean J. Pittock, Rochester, MN.
Submitted June 12, 2014
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.